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A B S T R A C T
Infection remains an important cause of morbidity and mortality. Natural defenses to infection are
mediated by intrinsic/innate and adaptive immune responses. While our understanding is considerable it
is incomplete and emerging areas of research such as those related to the immune-metabolic axis are only
beginning to be appreciated. There is increasing evidence showing a connection between immune
signalling and the regulation of sterol and fatty acid metabolism. In particular, metabolic intermediates of
cholesterol biosynthesis and its oxidized metabolites (oxysterols) have been shown to regulate adaptive
immunity and inflammation and for innate immune signalling to regulate the dynamics of cholesterol
synthesis and homeostasis. The side-chain oxidized oxysterols, 25-hydroxycholesterol (25HC) and
vitamin D metabolites (vitamin D3 and vitamin D2), are now known to impart physiologically profound
effects on immune responses. Macrophages play a frontline role in this process connecting immunity,
infection and lipid biology, and collaterally are a central target for infection by a wide range of pathogens
including viruses and bacteria, especially intracellular bacteria such as mycobacteria. Clinical
manifestations of disease severity in the infected host are likely to pay tribute to perturbations of
the metabolic-immune phenomena found in lymphocytes and myeloid cells. Historically and consistent
with this notion, vitamin D based oxysterols have had a long association with promoting clinical
improvements to patients infected with Mycobacterium tuberculosis. Hence understanding the role of
early metabolic mediators of inflammatory responses to infection in particular oxysterols, will aid in the
development of urgently needed host directed therapeutic and diagnostic design innovation to combat
adverse infection outcomes and antibiotic resistance.
ã 2016 Published by Elsevier Ltd.
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Cholesterol constitutes about 20% of lipids in the plasma
membrane playing a key role in the maintenance of membrane
integrity and fluidity, which impacts on a variety of cellular
physiology. For example, cholesterol rich microdomains, known as
lipid rafts, form a platform for interaction between membrane
bound receptors and their ligands to instigate signal transduction
[1]. Moreover, the cholesterol biosynthesis pathway has multiple
branches generating intermediate molecules, such as isoprenoids
and oxysterols that are vital for a diverse range of biochemical and
physiological processes such as in vesicular trafficking, steroidFig. 1. Cholesterol and oxysterols synthesis pathway. The mevalonate pathway sta
dehydroxycholesterol, which is a substrate for cholesterol and vitamin D3. The source
different types of oxysterols. Enzymes involved in the synthesis are shown in lig
hydroxycholesterol. The source/sink glyph Ø indicates dietary source. See Table 1 for gly
reader is referred to the web version of this article.)
Please cite this article in press as: S.Y. Bah, et al., Immune oxysterols: Role 
Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04.015hormone production, protein prenylation and as metabolite based
effectors and regulators of the immune response [2].
Structurally, a cholesterol molecule consists of four steroid
rings with a hydroxyl group attached on the A-ring and a
hydrophobic 8-carbon side-chain. Cholesterol biosynthesis uses
Acetyl-CoA as the primary building block, leading to the
production of isoprenoids and sterols from the mevalonate and
lanosterol pathways, respectively. Notably, in the Kandutch-
Russell pathway of the sterol biosynthesis branch, 7-dehydrocho-
lesterol is also used for the synthesis of vitamin D3 (Fig. 1).
Furthermore, essential metabolites are generated downstream
from cholesterol itself and include, bile acids, steroid hormonesrts with Acetyl-CoA and produces Lanosterol. Lanosterol is converted into 7-
 symbol on vitamin D2 indicates dietary source. Cholesterol is hydroxylated into
ht red colours. NB; 25(R)26-hydroxycholesterol is also commonly called 27-
ph notation. (For interpretation of the references to colour in this figure legend, the
in mycobacterial infection and inflammation, J. Steroid Biochem. Mol.
Table 1
SBGN [20] notations.
Symbol Description Symbol Description
Connecting arc Process node
Production arc Uncertain process
Catalytic arc Omitted process
Inhibition arc Perturbing agent
Modulation arc Macromolecule
Or operator Sorce or sing
AND operator Clone marker
Association arc Phenotype
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been long established to regulate immune responses, oxysterols
have only recently been recognised to have roles in immunity and
inflammation outside cholesterol homeostasis. In particular, oxy-
sterols such as 25-hydroxycholesterol (25HC) have been shown to
have both pro- and anti-inflammatory effects on immune response
and broadly suppresses in a cell intrinsic manner viral infection
[3,4] while the dihydroxy form of 25HC, 7a,25-dihydroxycholest-
4-en-3-one (7a,25HC) is known to be vital for B-cell maturation
and function [7]. Furthermore, 1,25-dihydroxyvitamin D3 (1,25
(OH)2D3) and 1,25(OH)2D2 oxysterols also affect immune
responses and have been implicated in susceptibility to infectious
diseases such as tuberculosis [5,6]. There have been a number of
excellent reviews discussing the role of oxysterols, specifically
25HC, in modulating the immune response and we refer the
readers to these [7,8]. However, a role in the context of specific
host-pathogen interactions and how this new functional class of
oxysterols (termed immunosterols) are regulated by the immune
system has received little attention, yet remains a key question
towards understanding a role of the immune-metabolic axis in
host response to infection and inflammatory diseases.
Infectious diseases are responsible for a greater proportion of
morbidity and mortality in many parts of the world, especially in
countries with poor resources and health infrastructures. These
diseases are caused by pathogens ranging from bacteria; such as
pneumococcal infections, a leading cause of pneumonia, M.
tuberculosis, which causes Tuberculosis (TB), to parasites; Plasmo-
dium species responsible for malaria and viruses such as the
human immunodeficiency virus causing HIV/AIDS [9]. Notably, TB
is responsible for a large proportion of deaths due to infectious
diseases with an incidence rate of about 9 million cases and an
estimated 1.5 million deaths per year [10]. The host response to
mycobacterial infection is not fully understood but is thought to be
primarily T cell mediated. BCG vaccine, the only licenced vaccine
against TB, has variable efficacy ranging from 0 to 80% in
preventing pulmonary TB, the form of the disease responsible
for transmission [11,12]. Therapeutically, TB is treated by a
combination of antibiotics, including isoniazid known to inhibit
the synthesis of mycolic acid, an essential mycobacterium
membrane lipid. However, the rapid evolution of multiple
antibiotic-resistant M. tuberculosis strains is making treatment
of TB a significant challenge [13]. Hence there is a need to find new
treatments.
Host derived fatty acids and cholesterol are known to be
catabolised by M. tuberculosis providing important substrates for
energy or biosynthetic precursors for a range of mycobacterial
lipids, such as mycolic acid required for its cell wall [14]. In this
regard, targeting TB lipid catabolic pathways or in combination
with host lipid metabolism has future potential to expand the
range of treatment options [15]. Intriguingly, our recent discovery
for a direct role of sterol lipids in governing anti-infective immune
responses supports the innovative concept for adjuvant-based
therapies to treat infections. Indeed, many years ago in the pre-
antibiotic era vitamin D was used to treat TB and over the last
decades its role in TB immune response has become more apparent
[16,17]. Furthermore, polymorphisms in the vitamin D receptor
(VDR) gene are associated with increased susceptibility to TB
disease [18] and African Americans who have low serum vitamin D
levels are less able to control the infection in comparison with
white American counterparts exhibiting higher vitamin D levels.
This raises a central unanswered question of whether cholesterol
and its intermediates have a direct anti-mycobacterium activity as
well as immune modulating properties in tuberculosis infection.
Herein we firstly discuss the biosynthesis of oxysterols. Next we
outline the immune regulation of select oxysterols production,
specifically 1,25(OH)2D and 25HC, and how the immune regulatedPlease cite this article in press as: S.Y. Bah, et al., Immune oxysterols: Role 
Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04.015oxysterols further modulate the immune responses. Lastly, the
contributions of oxysterols in an infectious diseases setting
(especially in Tuberculosis) are explored.
2. Synthesis of oxysterols
For the purpose of this review we briefly summarise the
synthesis of oxysterols from the mevalonate-cholesterol biosyn-
thesis pathway. This pathway starts with acetyl-CoA, whereby 3-
Hydroxy-3-Methylglutaryl Coenzyme A Synthase (HMGCS) catal-
yses the condensation of acetyl-CoA with acetoacetyl-CoA to
generate 3-Hydroxy-3-methylglutarly CoA (HMG-CoA) as part of
the first step in the mevalonate pathway (Fig. 1) [2,19]. HMG-CoA is
converted into mevalonate by 3-Hydroxy-3-methylglutarly CoA
reductase (HMCGR), and through multiple steps is subsequently
converted to lanosterol. Lanosterol forms the first substrate of the
Bloch and Kandutsch-Russell pathway of cholesterol biosynthesis
[2]. Oxysterols are enzymatically produced from cholesterol via the
addition of a hydroxyl group to cholesterol steroid rings or the side
chain. In addition, non-enzymatic generation of oxysterols, such as
vitamin D from 7-dehydrocholesterol produced in the Kandutsch-
Russell pathway, with the help of UV radiation from the sun on the
skin.
Fig. 1 summarises the pathways for production of a range of the
key oxysterols discussed in this review. To help avoid ambiguity, all
pathway diagrams illustrated in this review use the glyphs and arcs
from the systems biology graphical notation (SBGN) [20] shown in
Table 1. Of these oxysterols, 25-hydroxycholesterol (25HC) has
emerged as one of the most recent immune oxysterols with a range
of inflammatory and anti-inflammatory effects [3,4,21–23]. 25HC
is synthesised by different enzymes found in the mitochondria or
endoplasmic reticulum (ER). In the ER, 25HC is synthesised by a
stringently immune-regulated hydroxylase, cholesterol-25-hy-
droxylase (CH25H). Cytochrome P450 3A4 (CYP3A4) which is
not immune regulated can also catalyse the hydroxylation of the
25th carbon on the cholesterol side chain [24]. In mitochondria
CYP27A1 catalyses the hydroxylation of cholesterol at the 27th
carbon position to form 25(R) 26-hydroxycholesterol [25]. CYP7B1,
a 7a-hydroxylase catalyses the 7a hydroxylation of 25HC and 25
(R) 26-hydroxycholesterol to produce 7a-25diHC and 7a-25(R),26
dihydroxycholesterol respectively (Fig. 1). The biologically active
form of 7a-25diHC is inactivated by conversion into 7a,25-
dihydroxycholest-4-en-3-one by HSD3B7 leading to the degrada-
tion of this potent immune effector (Fig. 1). CYP3A4 can alsoin mycobacterial infection and inflammation, J. Steroid Biochem. Mol.
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hydroxycholesterol. Other important oxysterols includes 7a
hydroxycholesterol, which is produced by CYP7A1 through alpha
hydroxylation of the 7th carbon and 24HC, catalysed by CYP46A1.
24HC is further hydroxylated at the 7th position to produce 7a,
24S-dihydroxycholesterol.
Hydroxylated vitamin D3 (1,25(OH)2D3) representing another
important immune oxysterol can also be produced from a
precursor of cholesterol. In this case, pre-vitamin D3 is produced
from 7-dehydrocholesterol in the skin with the action of UV
radiation from the sun and undergoes spontaneous isomerisation
to produce vitamin D3. The biologically active form of vitamin D
1,25-dihydroxyvitamin D (1,25(OH)2D) is synthesised from its pro-
hormone (vitamin D) in two sequential hydroxylation steps by 25-
hydroxylases (CYP27A1, CYP2R1) and (CYP27B1) in the liver and
kidney, respectively [26,27]. The active vitamin D hormone is
inactivated by CYP24A1 by addition of a hydroxyl group at the 24th
position of both 25 hydroxycholesterol and 1,25 hydroxycholes-
terol leading to the degradation of the hormone as shown in Fig. 1.
3. Immune regulation of oxysterol synthesis
While oxysterols can be produced from many cellular sources,
only a few have been documented to be under stringent immune
regulation. In this case, immune cells, especially activated macro-
phages and monocytes, have been shown to be a rich source for
immunosterols generation upon infection.
The CH25H gene is stringently and cell type specifically
immune inducible in a highly cell-specific manner. In particularFig. 2. Immune regulation of oxysterol production. A) Regulation of CH25H synthesis an
and gamma. B) Immune regulation of CYP27B1 and vitamin D receptor (VDR) by TLRs.
Please cite this article in press as: S.Y. Bah, et al., Immune oxysterols: Role 
Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04.015macrophages can produce and secrete copious amounts of 25HC
upon immune activation but its expression is notably silent in
quiescent immune cells [28]. The induction of CH25H expression in
bone marrow derived dendritic cells and macrophages has been
shown to occur upon the activation of Toll like receptor (TLR)
agonists such as, lipopolysaccharide (LPS) and poly I:C, that are TLR
4 and TLR 3 agonists, respectively [29,30]. Injection of LPS into
healthy volunteers has also been shown to increase the serum
concentration of 25HC [29]. Notably, an inflammatory repressor,
termed ATF3 that is activated in an interferon dependent manner,
can potently inhibit the immune stimulated production of 25HC
[31,32] as shown in Fig. 2. The mechanism of this TLR mediated
activation of CH25H relies on type I interferon production, which
subsequently signals through the Janus activated kinase, signal
transducer and activator of transcription factor 1 (JAK/STAT1)
pathway to induce the expression of CH25H (Fig. 2A) [3,4,29].
Treatment of macrophages and DCs with type I interferon (IFN-a,
IFN-b) and interferon-gamma (IFN-g) induces rapid but transient
expression of CH25H in a STAT1 dependent manner [3]. In murine
models the stimulation of CH25H upon infection is strongly
dependent on interferon involving the rapid recruitment and
binding of STAT1 to the CH25H promoter [3]. This study showed a
direct molecular coupling of the inflammatory response to the
production of 25HC.
In macrophages, CYP27B1 production of 1,25(OH)2D can also be
regulated by activation with TLR ligands (Fig. 2B) or cytokines such
INF-g but not parathyroid hormone and depends on the
availability of 25-hydroxyvitamin D [33]. Type II interferon, IFN-
g stimulates the hydroxylation of 25 hydroxyvitamin D to produced hydroxylation of cholesterol to produce 25HC through TLR4 and interferon alpha
 See Table 1 for glyph notation.
in mycobacterial infection and inflammation, J. Steroid Biochem. Mol.
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opposing effect. Although the precise molecular details have yet to
be elucidated, in monocytes, TLR mediated induction of the
expression of 1a-hydroxylase has been shown to involve crosstalk
between the JAK-STAT, NF-kB and p38 signalling pathways that act
to coordinate the binding of C/EBPb to the 1a-hydroxylase gene
promoter region to induce expression [34]. CYP24A1 catalyses the
catabolic inactivation of hydroxylated vitamin D through the
hydroxylation of 25 hydroxyvitamin D or 1,25(OH)2D at the 24th
position. IFN-g, a Th1 cytokine, has also been found to up-regulate
CYP27B1 to produce 1,25(OH)2D while the Th2 cytokine IL-4
induces the catabolism of the active form of vitamin D hormone
through the induction of 24 hydroxylase CYP24A1 [35]. This
suggests that Th1 and Th2 T cell subsets have different and
opposing effects on the vitamin D metabolism. The induction of
1,25 dihydroxyvitamin D can have both autocrine and paracrine
effects through binding to its nuclear vitamin D receptor (VDR) to
regulate host defence genes.Fig. 3. 25 hydroxycholesterol regulation of immune responses. 25HC plays a key role in
expression of IL-8, IL-6 and MCSF while inhibiting the production of mature IL1-b by inhi
formation of STING/cGAMP complex that phosphorylates TBK, which further phosphor
Please cite this article in press as: S.Y. Bah, et al., Immune oxysterols: Role 
Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04.0154. Oxysterol regulation of immune responses
4.1. Effect of 25 hydroxycholesterol on immune responses
The up regulation of CH25H in macrophages and DCs by
inflammatory mediators indicated a potential function of 25HC
towards innate immune regulation [3,4,29]. Subsequent studies
demonstrated that 25HC can impart both pro- and anti-inflamma-
tory effects on immune responses [3,20,21,33]. Infection with virus
and bacterial pathogens like M. tuberculosis leads to production of
type I interferon and thereby rapidly inducing CH25H to generate
25HC. In its role as an anti-inflammatory molecule, 25HC blocks the
activation of the Sterol Regulatory Enhancer Binding Protein
(SREBP) that regulates cholesterol biosynthesis and inflammasome
activity. Specifically, 25HC has been shown to curtail inflammasome
activity (via NLRP3) and subsequent IL-1b production (Fig. 3) [22].
However, a complex regulatory picture is emerging as inhibition of
SREBP reduces flux in the sterol pathwayand leads to the stimulator
of interferon genes (STING) forming a complex with cyclic-GMP- regulating B-cell functions. Through an unknown mechanism 25HC enhances the
biting SREBP. Inhibition of SREBP also modulates sterol pathway flux resulting in the
ylates IFR3 to activate expression of IL1-b. See Table 1 for glyph notation.
in mycobacterial infection and inflammation, J. Steroid Biochem. Mol.
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STING/cGAMP complex further phosphorylates TANK binding
kinase 1 (TBK1) that phosphorylates IRF3, which in turn activates
the expression of IL1-b [37] (Fig. 3). Collectively these studies are
indicative of an immune circuit that employs both negative and
positive feedback and which would be consistent with both anti-
and pro-inflammatory roles.
Evidence for 25HC acting as a pro-inflammatory molecule, has
been provided by studies that show 25HC can augment the
production of other pro-inflammatory cytokines and chemokine
such as IL-6, IL-8 and macrophage colony stimulating factor (M-
CSF) in macrophages. The 25HC activation of these pro-inflamma-
tory cytokines has been suggested to be dependent on the NFkB
binding to their promoter regions [21]. Also, 25HC induces the
production and release of the pro-inflammatory cytokine CCL5 in
the RAW264.7 macrophage cell line [29]. CCL5 is a chemokine that
recruits more cells to the site of infection, which leads to the
amplification of the immune response and inflammation. Howev-
er, caution should be taken when interpreting experiments using
high levels (>10 mM) of 25HC. Altogether, these studies point to a
highly complex feedback regulation that is yet to be fully
understood but is suggestive of 25HC ability to tune toward anti-
and pro-inflammatory immune control depending on cell and
immunological context.
At present, 25HC and 7a,25-dihydroxycholest-4-en-3-one
(7a,25HC) are known to play a key role in the adaptive arm of the
immune system through regulation of B-cell function. B-lympho-
cytes, as important components of the adaptive immune response,
are responsible for the production of antibodies to protect against
infection. Antibody production involves immunoglobulin class
switching to combat different pathogens. Treatment of naïve B cell
with nanomolar concentrations of 25HC in vitro results in
suppression of class switching and reduced levels of IgA [28].
Mutant mice that lackCH25H producedsignificantlyhigher levelsof
IgA compared to wild type indicating that 25CH also suppress the
class switching in vivo. 7a,25HC which, is a further oxidized form of
25HC, is a ligand for EBI2 (Epstein-Bar virus induce gene in B cells)
[38]. EBI2 is a G-protein coupled receptor expressed by cells of the
immune system and B cells have been shown to migrate towards
concentration gradients of 7a,25HC. The expression of EBI2 is
important in the positioning of B cells close to locations where they
will encounter antigen in lymphoid organs and is involved in the
distribution of B cells into the boundary between B and T cell zones
[23,38,39]. Furthermore, mice lacking CH25H cannot produce
immune activated 25HC and 7a,25HC and accordingly have reduced
humoral immunity. This is due to a failure in correctly positioning
activated B cells within the spleen [38].
The involvement of 25HC and 7a,25HC in T cell responses has
not been intensively investigated to date but are also likely to play a
significant role. In this regard a very recent study has shown that
7a,25HC through its interaction with EBI2 promote the migration
of activated CD4+ T cells into inflamed tissues in experimental
autoimmune encephalomyelitis [40] as summarised in Fig. 3.
It is also worth noting that 25HC has the potential to activate
the Liver X receptors (LXRs), however, the immune-regulated
functions of 25HC appear to be independent of LXRs [3,4].
Although not discussed in this review, LXRs are also known to
play a role in immunity and inflammation [8]. LXRs are ligand
activated transcription factors. LXR ligands include oxysterols such
as 22 hydroxycholesterol (22(R)-HC) and are known to mediate
potent anti-inflammatory effects [41,42].
4.2. Vitamin D regulation of innate and adaptive immune responses
The modulation of immune responses by vitamin D has been
recognised for many years. Vitamin D functions through thePlease cite this article in press as: S.Y. Bah, et al., Immune oxysterols: Role 
Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04.015Vitamin D Receptor (VDR), which is expressed by most immune
cells. VDR is a nuclear hormone receptor that acts as a ligand-
activated transcription factor composed of DNA and vitamin D
binding domains. Binding of vitamin D results in the hetero-
dimerization with retinoic acid receptor (RXR) and binding to
vitamin D response elements (VDREs) of target genes. This results
in the recruitment of other factors such as histone modification
enzymes to induce chromatin remodelling to either activate or
suppress gene expression [43]. Besides binding to the VDREs,
vitamin D can also affect gene expression through association of
the VRD/RXR complex with other transcription factors and
preventing binding and activation of target genes. For example,
1,25(OH)2D inhibition of the cytokine IL-2 is mediated through
complex formation between the VDR/RXR complex with the
transcription factor, nuclear factor of activated T-cells (NF-AT),
activator protein 1 (AP-1) complex preventing binding of NF-AT to
its binding site [44].
VDR activation by 1,25(OH)2D promotes the differentiation of
monocytes into mature macrophages [45,46], enhances monocyte/
macrophage chemotactic ability and has been shown to increase
phagocytosis of M. tuberculosis [47,48]. TLR4 and its CD14 co-
receptor are also significantly induced by 1,25(OH)2D that
altogether underscore an important role in innate immunity for
hydroxylated vitamin D [49]. VDREs are found in hundreds of
genes including immune related genes such as CD14, cathelicidin
antimicrobial peptide (CAMP) and beta defensin (DEFB4) [50].
Accordingly, 1,25(OH)2D has the ability to re-programme immune
cells such as macrophages toward host-defence. Indeed studies
have found the promoter regions of CAMP and DEFB4 genes to be
bound by the VDR/RXR complex in a 1,25(OH)2D dependent
manner and expression of CAMP induced in cells including
monocytes and macrophages [51]. Importantly, the anti-microbi-
cidal effects of 1,25(OH)2D on pathogens is believed to be mediated
to a large extent by these antimicrobial peptides [52,53]. CAMP is
found in the lysosomes of immune cells such as macrophages and
neutrophils playing a critical role in innate immunity with broad
antimicrobial effects. Following treatment with 1,25(OH)2D,
macrophages show the greatest induction of cathelicidin [54].
Beside the direct antimicrobial action on the pathogens, CAMP and
beta-defensins are also important chemo-attractants of other
immune cells such as neutrophils and monocytes. Another
important anti-microbial protein, hepcidin (HAMP) supports the
growth and survival of M. tuberculosis by controlling the export of
cellular iron which is essential for bacterial growth [55]. Studies
have shown that 1,25(OH)2D down regulates HAMP expression,
suggesting that deprivation of iron limits mycobacterial growth
[56].
Similar to 25HC, studies have also suggested that hydroxylated
vitamin D has anti-inflammatory effects on macrophages. In
macrophages, 1,25(OH)2D reduces the expression of TNF-a by up
regulating IkB-a via blocking the translocation of NF-kB into the
nucleus to induce the expression of TNF-a [57]. In THP-1 cell lines
1,25(OH)2D has been shown to repress the expression of IL-12 and
IL-10 cytokines [58]. The early repression of these genes could be a
mechanism for dampening inflammation to reduce tissue damage
after clearing infection and maintenance of immune homeostasis.
Altogether, these studies point to a highly complex feedback
regulation that is yet to be fully understood but is suggestive of 1,25
(OH)2D ability to tune toward anti- and pro-inflammatory immune
control depending on cell and immunological context.
The action of1,25(OH)2D, like25HC, isnot restrictedtothe innate-
immune arm of immunity. 1,25(OH)2D also influences the adaptive
immune system by modulating the proliferation of T cells and
production of cytokines. Naïve CD4 T cells can differentiate to
become different subsets including Th1 and Th2 helper cells, which
combat intracellular and extracellular pathogens respectively. 1,25in mycobacterial infection and inflammation, J. Steroid Biochem. Mol.
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different helper subsets by affecting antigen presentation and
cytokine production. Dendritic cells, which are the professional
antigenpresenting cells are primary targets of vitamin D.1,25(OH)2D
reduces the antigen presentation ability of DCs by down regulating
the expression of major histocompatibility complex class II (MHCII)
and co-stimulatory molecules involved in antigen presentation
including CD86, CD80 and CD40 [59] as shown in Fig. 4. 1,25(OH)2D
can also reduces the expression of IFN-g through the binding of the
VDR/RXR complex to the silencer promoter region of the gene [60].
Stimulation of human T cells with 1,25 dihydroxyvitamin D initiates
VDR signalling which correlates with suppression of IFN-g and IL-10
production and modulation of CCR10 homing receptor [61].
However, some studies showed an opposite effect of 1,25(OH)2D
onIL-10,suggestingIL-10inductionbythehormoneinhumanB cells.
Furthermore, 1,25(OH)2D affects T cell proliferation, cell cycle
progression, and the ability of T cells to secrete cytokines and inhibit
the expression of IL-2, which is an important growth factor for T
lymphocytes. T cell cytokine secretion and cell cycle progression
from G1a-G1b were shown to be inhibited by 1,25(OH)2D in in vitro
experiments. 1,25(OH)2D influences naïve T cell development
towards a Th2-type response by promoting the expression of Th2
cytokines (IL-4, IL-5 and IL-10) while inhibiting the synthesis of Th1
cytokines (IL-2, IL-12 and IFN-g) [62,63].
In summary the immune oxysterols, 25HC and 1,25(OH)2D are
under stringent regulation by the immune system. Collectively the
investigations of the immune oxysterols, 25HC and 1,25(OH)2D, are
indicative of an immune regulatory circuit that employs both
negative and positive feedback and which would be consistentFig. 4. 1,25-dihydroxyvitamin D3 modulation of immune response. 1,25(OH)2D3 increa
transported into the lysosome to kill pathogens. Vitamin D also reduces the expressio
subsequently reduce antigen presentation and initiation of the adaptive immune respo
Please cite this article in press as: S.Y. Bah, et al., Immune oxysterols: Role 
Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04.015with both anti- and pro-inflammatory roles. Accordingly, studies to
date have documented evidence for a range of roles of oxysterols
on inflammatory responses to infection. Hence, immune context
and pathogen specific responses are likely to shape the progression
for either beneficial or harmful outcomes. As mentioned TB is
responsible for a larger proportion of death due to infectious
diseases yet the role of immune oxysterols in mycobacterial
infection has not yet been fully appreciated. Next we will review
how sterol and oxysterols might impact on tuberculosis infection.
5. Pathogenesis of tuberculosis
Members of the mycobacterium tuberculosis complex that
include, Mycobacterium tuberculosis, M. bovis and M. africanum,
cause tuberculosis. The disease is airborne transmitted by air
droplets containing the bacteria and once inhaled by a susceptible
host, M. tuberculosis is phagocytosed by alveolar macrophages.
Once activated, alveolar macrophages release tumor necrosis alpha
(TNF-a) and other inflammatory cytokines and chemokines that
recruit more cells to the site of infection resulting in the formation
of cholesterol rich granulomas [64]. Following infection about 90%
of individuals develop latent TB, few people clear the infection,
while between 10 and 15% of infected individuals develop active
TB. Some individuals with latent TB can develop active TB during
their lifetime, which is attributed to changes in immune
regulation. The risk of reactivation is higher in HIV infected
individuals who have low CD4 counts. The fusion of the phagosome
and lysosome containing bacteriolytic peptides is important in the
killing and degradation of pathogens. M. tuberculosis, however, hasses the expression of antimicrobial peptides such as CAMP and DEFB4, which are
n of TLR4. It further, supresses the expression of CD80, CD86 and MHC II, which
nse. See Table 1 for glyph notation.
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survival in macrophages with limited nutrient availability [65].
M. tuberculosis generally infects the lungs resulting in pulmo-
nary tuberculosis, which represent the major form of TB. Patients
suffering from pulmonary TB are most infectious when they cough
and usually present with abnormal chest X-rays. However, the
bacteria can invasively spread to other parts of the body from the
lungs resulting in extrapulmonary TB [66]. TB can affect the brain
and the surrounding meninges causing meningitis. The bacteria
can also enter the bloodstream and spread to different parts of the
body to cause miliary TB, which mostly affects young children and
immunocompromised individuals [67].
Mycobacterial cellular components are recognised by pattern
recognition receptors (PRRs) such as Toll like receptor 2 (TLR2),
TLR4 and TLR9, which subsequently stimulate and activate
immune cells. TLR signalling leads to the production of pro-
inflammatory cytokines such as TNF-a, IL-12 and IFN-g, which are
important in T-cell mediated immune response to mycobacterial
infection [68]. IFN-g activates macrophages to phagocytose and
degrade the bacteria and IL-12 stimulates natural killer (NK) cells
to produce more IFN-g. TNF-a is important in the formation and
maintenance of granulomas to prevent the spread of the bacteria
[69]. Also produced during mycobacterial infection are anti-
inflammatory cytokines, such as IL-10 and tumor growth factor
beta (TGF-b), which counteract the responses of the pro-
inflammatory cytokines to maintain immune homeostasis. How-
ever, these anti-inflammatory cytokines can equally exacerbate TB
and can influence latent TB reactivation [70].
5.1. Mycobacteria can use sterols for carbon and energy
In the context of a granuloma, the bacteria (inside and outside
cells) have limited nutrient and carbon source, with perhaps the
exception of lipid loaded foamy macrophages [71]. In particular, in
intra-cellular infectedfoamymacrophagesM. tuberculosis is found to
be associated with lipid raft membranes. The finding that the M.
tuberculosis genome encodes more than 250 genes potentially
involved in lipid metabolism was among the first indications of the
importance of lipids in mycobacterial pathogenesis [72]. Such
groups of genes include the mce4 operon, intracellular growth (igr)
operon and acyl-CoA dehydrogenases (ACAD) genes, which are
genetically located in the so-called “Cho region” spanning a 50 kb
region, containing about 80 genes many of which seem to be largely
implicated in cholesterol metabolism [73]. Other studies have
identified a different set of genes used by M. tuberculosis for
catabolic degradation of both the sterol rings and cholesterol side
chain located elsewhere in the bacterial chromosome outside the so
called “Cho-region” [74]. Mce4 member genes have been demon-
strated to be essential for the import and catabolism of cholesterol
to enable mycobacterial persistence in murine infection models
[75,76]. Wild type M. tuberculosis is able to grow in minimal media
with cholesterol as the only carbon source while mce4 mutants fail
to grow, indicating the ability of the bacteria to use cholesterol and
its dependency on mce4 for cholesterol utilization. Moreover, 14C-
radiolabeling of cholesterol shows that the carbon at position 4 on
the A ring is converted to carbon dioxide (CO2) while carbon 26 on
the side chain is assimilated by M. tuberculosis into its membrane
lipids including phthiocerol dimycocerosate (PDIM), which is an
important virulence factor [75].
Once internalised by the bacteria, the cholesterol side chain and
sterol rings are degraded to generate metabolites that either serve
as precursors in the anabolic pathways to synthesis of mycolic
acids and other lipids, which are important bacterial cell wall
components or fed into the tricarboxylic acid cycle (TCA cycle). The
first step in cholesterol degradation involves conversion of
cholesterol by 3b-hydroxysteroid dehydrogenase (3b-HSD) toPlease cite this article in press as: S.Y. Bah, et al., Immune oxysterols: Role 
Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04.015produce cholest-4-en-3-one. 3b-HSD is encoded by Rv1106c and
uses NAD+ as co-factor to oxidise cholesterol and pregnenolone
into their respective 3-keto-4-ene [77]. Cholest-4-en-3-one is
further metabolised to produce 4-adrostenedione, which under-
goes trans-axial removal of the C1(a) and C2(b) hydrogen atoms of
the cholesterol A ring to generate 1,4-adrostenedione (ADD)
(Fig. 5). M. tuberculosis Rv3537 (KstD) gene encodes 3-ketosteroid-
delta-1-dehydrogenase and disruption of this gene resulted in
growth inhibition in minimal media containing cholesterol as the
sole carbon source [78]. KshA/B Rieske oxygenase catalyses the 9-
hydroxylation of ADD into 9-hydroxy-1,4,androtene-3-17-diene,
which is unstable, resulting in opening of the cholesterol A ring and
aromatisation of the B ring to produce 3-hydroxy-9,10-seconan-
drost-1,3,5(10)-triene-9,17-dione (3-HAS) [79]. KshA encoded by
Rv3526 is the oxygenase and KshB encoded by Rv3571 [79]. The
subsequent three steps lead to the generation of 9,19-dioxo-
1,2,3,4,10,19-hexanorandrostan-5-oic acid (DOHNAA) and 2-hy-
droxy-hex-2,4-dienoic acid (HHD) (Fig. 5). HHD is converted into
pyruvate and propionyl-CoA. Pyruvate is metabolised further to
feed into the TCA cycle while the propionyl-CoA is converted into
Methylmalonyl-CoA, which is a precursor used by the bacteria to
synthesise cell wall lipids phthiocerol dimycocerosates (DIM) and
sulfolipid-1 which are important components of bacterial cell wall.
DIM is important in the pathogenesis of the bacteria participating
in mycobacterial infection of macrophages and inhibition of
phagosome acidification [80].
Little is known about the degradation of the cholesterol side
chain. Cyp125 catalyses the hydroxylation of cholesterol and other
steroids at C27 on the side chain [81]. Cyp125 is encoded by
Rv3545c in the intracellular growth operon (igr) also encoding
other genes important for intracellular survival of the bacteria in
macrophages and spleen of infected mice [82]. Once hydroxylated
by the Cyp125, the side chain undergoes several steps of
b-oxidation catalysed by oxidation enzymes including fadA5,
fadE28, fadE30 and fadE34 [74]. b-Oxidation of the side chain
results in the production of propionyl-CoA and Acetyl-CoA (Fig. 5).
Acetyl-CoA is further metabolised to produce malonyl-CoA serving
as a precursor for fatty acid biosynthesis by mycobacteria through
fatty acid synthase I (FAS I) and FAS II. Subsequently the end
product of the fatty acid anabolism is the synthesis of mycolic acid
and cell mycobacterial wall lipids playing an important role in
pathogenesis. Isoniazid, a frontline mycobacterial antibiotic, acts
by inhibiting one of the FAS II enzymes (InhA) in the mycolic acid
biosynthesis pathway (Fig. 5) [83,84]. Pks13 is the final enzyme
catalysing the condensation step to produce mycolic acids [85].
Hence there is accumulating evidence that M. tuberculosis has the
ability to use sterols, in part, for not only energy and anabolic
processes but also more importantly to promote its own lipid
based virulence factors. However, it is worth noting that there is a
high degree of redundancy in the ability of M. tuberculosis to use a
variety of other carbon sources and although, it is possible that
cholesterol or more generally sterols may be critically required at
specific sites or times during the infection cycle, it is conceivable
that other functions, perhaps additionally related to the degrada-
tion of immune-sterols, may also be at play. In the latter case, M.
tuberculosis could import host sterols, including the immunoster-
ols, using the mce4 transport system. In this scenario, immuno-
modulatory 25HC and 1,25(OH)2D can be imported by the bacteria
potentially reducing in the infected cell any host oxysterol
mediated immune response.
Alteration of host cholesterol synthesis and homeostasis also
appear to have an impact on M. tuberculosis. Statins are a well-
established class of drug for lowering cholesterol levels by
targeting HMGCR in the cholesterol biosynthesis pathway and
are highly efficacious in treating hypercholesterolemia. In this
regard, it is worth noting that statins impart beneficial anti-in mycobacterial infection and inflammation, J. Steroid Biochem. Mol.
Fig. 5. Uptake and catabolism of sterols by M. tuberculosis. Cholesterol is metabolised by the bacteria to produce intermediates that it can use as a source of energy through the
TCA and biosynthesis of cell wall components such as mycolic acids and Sulfulipid-1. Blue; mycobacterial degradation of the cholesterol sterol rings, Pink; degradation of
cholesterol side chain, orange; Synthesis of mycobacterial cell wall lipids and purple; generated pyruvate feed into the TCA cycle. See Table 1 for glyph notation.
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and monocyte derived macrophages (MDM) from patients
undergoing statin treatment were found to be more resistant
and better able to control M. tuberculosis compared to healthy
untreated donors [86]. Mice treated with statins (Simvastatin and
Rosuvastatin), and then infected with M. tuberculosis have
enhanced phagolysosomal maturation and autophagy and restrict
infection in comparison with to non-statin treated controls [86]. In
further murine studies co-treatment with statins and the antibiotic
Rifampicin showed synergistic effects in inhibiting M. tuberculosis
infection [87]. More extensive investigations in patients with TB
are required and especially well controlled clinical evaluations
need to be conducted before any conclusions can be drawn about
use of statins or similar lipid-modulating therapies. Nevertheless,
the published literature provides indicators for future work toPlease cite this article in press as: S.Y. Bah, et al., Immune oxysterols: Role 
Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04.015better understand the pathophysiology of the host sterol pathway
in M. tuberculosis and in regulating immune responses.
6. Do oxysterols have a role during mycobacterial infection?
The intricate and complex molecular interplay between oxy-
sterols, immunity and M. tuberculosis outlined above supports the
notion that oxysterols could impact on infection at the intracellular
and systemic levels.
At the level of infected cell mycobacteria have the ability to use
sterols as a source of energy and carbon source for anabolic lipid
pathways. However nutritional immunity based on the suppres-
sion of cholesterol levels, mediated through the interferon
response, may make only a minor contribution due to redundancy
in the capacity of mycobacteria to use a wide range of alternative
energy and carbon sources. Alternatively, as the level of productivein mycobacterial infection and inflammation, J. Steroid Biochem. Mol.
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and lipid rafts, a reduction of cholesterol and as a consequence
lipid raft and foam cell formation could have a beneficial effect in
the control of mycobacterial infection. The formation of foam cells
and lipid droplets is a peroxisome proliferator-activated receptor
gamma (PPAR-g) driven process; and there is evidence showing
that 1,25(OH)2D treatment of cells limits M. tuberculosis growth
through the inhibition of PPAR-g mediated lipid droplet formation
[88]. In addition, blockade of cholesterol formation is also
restrictive for lipid droplet development. 25HC, is a well-
characterised potent inhibitor of intracellular cholesterol forma-
tion through preventing the nuclear import of SREBP and through
the proteosomal degradation of HMGCR [32]. While immune
activation of macrophages can lead to a transient but significant
decrease in cholesterol levels through the action of 25HC it is not
known whether this has any cell intrinsic antimycobacterial
activity. Further studies are required to investigate this possibility.
At the immune system level, oxysterols have critical roles in
mounting effective innate and adaptive immune responses. In
particular, 1,25(OH)2D mediated activation of macrophage VDR is
well known to promote an effective cell innate immune response
against M. tuberculosis through stimulating the production of
antimicrobial peptides. Furthermore, 25HC is critical for the
development of a healthy antibody response and as such will likely
have a contributory role in developing an appropriate adaptive
humoral immune response. Whether 25HC has any role in T-cell
immunity has yet to be explored, although CH25H is also up
regulated by T cells upon stimulation. Although yet to be
investigated for M. tuberculosis, it is now clear that 25HC
contributes to fighting against infection through modulating the
innate and possibly the adaptive immune arms acting, in part, via
the suppression of mevalonate-cholesterol biosynthesis pathways.
We speculate that cross talk and interplay between mycobac-
teria and oxysterols may impact the course of infection. In this
context M. tuberculosis encodes enzymes capable of catabolising
these immune oxysterols and at the intracellular level may counter
the anti-infective actions of the oxysterols. Extracellular M.
tuberculosis may reduce effective concentrations of paracrine
levels of immunosterols at sites on infection. At another cross talk
level, a critical macrophage innate-immune function involving
phagolysosomal maturation for the containment and killing of M.
tuberculosis can be countered by M. tuberculosis by producing
tryptophan aspartate containing coat protein (TACO). TACO coats
the phagosome membrane blocking its fusion with lysosomes.
Thus, TACO enables the mycobacterium to avoid the lysosomal
degradative enzymes and promotes the survival of intracellular M.
tuberculosis [89]. However, as a host counter measure, 1,25(OH)2D
enhances phagolysosomal maturation of M. tuberculosis phago-
somes and bacterial killing by effectively blocking the expression
of TACO [90].
7. Concluding remarks
Here, we have highlighted the significance of immune sterols in
regulating immunity and infection by mycobacteria and described
their frontline role in the process of connecting immunity to lipid
biology. We propose that the clinical manifestations of disease
severity in the infected host or indeed the progression from
infection to TB disease might depend on the balance between the
beneficial and harmful perturbations in the metabolic-immune
axis highlighted by the cholesterol metabolic network. In
particular, with regards to the synthesis and action of key immune
regulatory oxysterol-metabolites, 25HC and 1,25(OH)2D. Notably
M. tuberculosis has invested considerable genomic real estate to
encode enzymes capable of exploiting and catabolising these host
derived immune metabolites. This reinforces the suggestion ofPlease cite this article in press as: S.Y. Bah, et al., Immune oxysterols: Role 
Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04.015targeting in a concerted manner not only pathogen but also host-
derived metabolic pathways for combating microbial antibiotic
resistance and enhancing host protection against infection and
disease, especially against M. tuberculosis. Hence, we suggest that
understanding the role of early metabolic mediators of inflamma-
tory responses to infection will aid in the development of urgently
needed anti-infective therapeutics and host-directed therapies.
Acknowledgements
SYB is supported by joint doctoral scholarship from an MRC
Gambia-Darwin Trust Scholarship award. This work was also
supported in part by the BBSRC (BB/K019112/1). The authors thank
Wayne Hsieh for advice on graphical pathway notation. We thank
Widad Dantoft, Kevin Robertson and the reviewers for their helpful
comments.
Reference:
[1] M.B. Fessler, J.S. Parks, Intracellular lipid flux and membrane microdomains as
organizing principles in inflammatory cell signaling, J. Immunol. 187 (2011)
1529–1535.
[2] A. Mazein, W. Griffiths, T. Freeman, P. Ghazal, S. Watterson, H. Gibbs, et al.,
Regulation and feedback of cholesterol metabolism, Nat. Preced. (2011), doi:
http://dx.doi.org/10.1038/npre.2011.6315.1.
[3] M. Blanc, W.Y. Hsieh, K.A. Robertson, K.A. Kropp, T. Forster, G. Shui, et al., The
transcription factor STAT-1 couples macrophage synthesis of 25-
hydroxycholesterol to the interferon antiviral response, Immunity 38 (2013)
106–118.
[4] S.-Y. Liu, R. Aliyari, K. Chikere, G. Li, M.D. Marsden, J.K. Smith, et al., Interferon-
inducible cholesterol-25-hydroxylase broadly inhibits viral entry by
production of 25-hydroxycholesterol, Immunity 38 (2013) 92–105, doi:http://
dx.doi.org/10.1016/j.immuni.2012.11.005.
[5] T.Y.K. Chan, Vitamin D deficiency and susceptibility to tuberculosis, Calcif.
Tissue Int. 66 (2000) 476–478, doi:http://dx.doi.org/10.1007/s002230010095.
[6] N. Talat, S. Perry, J. Parsonnet, G. Dawood, R. Hussain, Vitamin D deficiency and
tuberculosis progression, Emerg. Infect. Dis. 16 (2010) 853–855, doi:http://dx.
doi.org/10.3201/eid1605.091693.
[7] J.G. Cyster, E.V. Dang, A. Reboldi, T. Yi, 25-Hydroxycholesterols in innate and
adaptive immunity, Nat. Rev. Immunol. 14 (2014) 731–743, doi:http://dx.doi.
org/10.1038/nri3755.
[8] N.J. Spann, C.K. Glass, Sterols and oxysterols in immune cell function, Nat.
Immunol. 14 (2013) 893–900. http://www.ncbi.nlm.nih.gov/pubmed/
23959186.
[9] C.J. Murray, K.F. Ortblad, C. Guinovart, S.S. Lim, T.M. Wolock, D.A. Roberts, et al.,
Global, regional, and national incidence and mortality for HIV, tuberculosis,
and malaria during 1990–2013: a systematic analysis for the Global Burden of
Disease Study 2013, Lancet (2014), doi:http://dx.doi.org/10.1016/S0140-6736
(14)60844-8.
[10] WHO, Global Tuberculosis Report 2015 (2015), http://apps.who.int/iris/
bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1.
[11] L.C. Rodrigues, V.K. Diwan, J.G. Wheeler, Protective effect of BCG against
tuberculous meningitis and miliary tuberculosis: a meta-analysis, Int. J.
Epidemiol. 22 (1993) 1154–1158.
[12] G.A. Colditz, T.F. Brewer, C.S. Berkey, M.E. Wilson, E. Burdick, H.V. Fineberg,
et al., Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis
of the published literature, JAMA 271 (1994) 698–702, doi:http://dx.doi.org/
10.1001/jama.1994.03510330076038.
[13] N.R.N.N.R. Gandhi, P. Nunn, K. Dheda, H.S. Schaaf, M. Zignol, D. van Soolingen,
et al., Multidrug-resistant and extensively drug-resistant tuberculosis: a threat
to global control of tuberculosis, Lancet 375 (2010) 1830–1843, doi:http://dx.
doi.org/10.1016/S0140-6736(10)60410-2.
[14] W. Lee, B.C. VanderVen, R.J. Fahey, D.G. Russell, Intracellular Mycobacterium
tuberculosis exploits host-derived fatty acids to limit metabolic stress, J. Biol.
Chem. 288 (2013) 6788–6800, doi:http://dx.doi.org/10.1074/jbc.M112.445056.
[15] R.R. Lovewell, C.M. Sassetti, B.C. VanderVen, Chewing the fat: lipid metabolism
and homeostasis during M. tuberculosis infection, Curr. Opin. Microbiol. 29
(2015) 30–36, doi:http://dx.doi.org/10.1016/j.mib.2015.10.002.
[16] D.E. Macrae, The use of calciferol in tuberculous conditions, Lancet 1 (1947)
135–136. http://bf4dv7zn3u.search.serialssolutions.com.myaccess.library.
utoronto.ca/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:
journal&rfr_id=info:sid/Ovid:emcl1&rft.genre=article&rft_id=info:doi/
&rft_id=info:pmid/&rft.issn=0140-6736&rft.volume=1&rft.is.
[17] G.B. Dowling, S. Gauvain, D.E. Macrae, Vitamin D in treatment of cutaneous
tuberculosis, Br. Med. J. 1 (1948) 430–435 http://www.pubmedcentral.nih.
gov/articlerender.fcgi?artid=2090361&tool=pmcentrez&rendertype=abstract
(accessed 12.01.16).
[18] L. Bornman, S.J. Campbell, K. Fielding, B. Bah, J. Sillah, P. Gustafson, et al.,
Vitamin D receptor polymorphisms and susceptibility to tuberculosis in West
Africa: a case-control and family study, J. Infect. Dis. 190 (2004) 1631–1641in mycobacterial infection and inflammation, J. Steroid Biochem. Mol.
S.Y. Bah et al. / Journal of Steroid Biochemistry & Molecular Biology xxx (2015) xxx–xxx 11
G Model
SBMB 4708 No. of Pages 12http://www.ncbi.nlm.nih.gov/pubmed/15478069\nhttp://jid.oxfordjournals.
org/content/190/9/1631.full.pdf\nhttp://jid.oxfordjournals.org/content/190/9/
1631.long.
[19] A. Mazein, S. Watterson, W.Y. Hsieh, W.J. Griffiths, P. Ghazal, A comprehensive
machine-readable view of the mammalian cholesterol biosynthesis pathway,
Biochem. Pharmacol. 86 (2013) 56–66, doi:http://dx.doi.org/10.1016/j.
bcp.2013.03.021.
[20] N. Le Novère, M. Hucka, H. Mi, S. Moodie, F. Schreiber, A. Sorokin, et al., The
systems biology graphical notation, Nat. Biotechnol. 27 (2009) 735–741.
[21] E.S. Gold, A.H. Diercks, I. Podolsky, R.L. Podyminogin, P.S. Askovich, P.M.
Treuting, et al., 25-Hydroxycholesterol acts as an amplifier of inflammatory
signaling, Proc. Natl. Acad. Sci. U. S. A. 6 (2014), doi:http://dx.doi.org/10.1073/
pnas.1404271111.
[22] A. Reboldi, E.V. Dang, J.G. McDonald, G. Liang, D.W. Russell, J.G. Cyster, 25-
Hydroxycholesterol suppresses interleukin-1-driven inflammation
downstream of type I interferon, Science 345 (2014) 679–684. http://www.
sciencemag.org/cgi/doi/10.1126/science.1254790.
[23] T. Yi, X. Wang, L.M. Kelly, J. An, Y. Xu, A.W. Sailer, et al., Oxysterol gradient
generation by lymphoid stromal cells guides activated B cell movement during
humoral responses, Immunity 37 (2012) 535–548.
[24] A. Honda, T. Miyazaki, T. Ikegami, J. Iwamoto, T. Maeda, T. Hirayama, et al.,
Cholesterol 25-hydroxylation activity of CYP3A, J. Lipid Res. 52 (2011) 1509–
1516.
[25] D.W. Russell, Oxysterol biosynthetic enzymes, Biochim. Biophys. Acta Mol. Cell
Biol. Lipids 1529 (2000) 126–135.
[26] D.E. Prosser, G. Jones, Enzymes involved in the activation and inactivation of
vitamin D, Trends Biochem. Sci. 29 (2004) 664–673.
[27] J.B. Cheng, M.A. Levine, N.H. Bell, D.J. Mangelsdorf, D.W. Russell, Genetic
evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase,
Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 7711–7715.
[28] D.R. Bauman, A.D. Bitmansour, J.G. McDonald, B.M. Thompson, G. Liang, D.W.
Russell, 25-Hydroxycholesterol secreted by macrophages in response to Toll-
like receptor activation suppresses immunoglobulin A production, Proc. Natl.
Acad. Sci. U. S. A. 106 (2009) 16764–16769, doi:http://dx.doi.org/10.1073/
pnas.0909142106.
[29] U. Diczfalusy, K.E. Olofsson, A.-M. Carlsson, M. Gong, D.T. Golenbock, O.
Rooyackers, et al., Marked upregulation of cholesterol 25-hydroxylase
expression by lipopolysaccharide, J. Lipid Res. 50 (2009) 2258–2264, doi:
http://dx.doi.org/10.1194/jlr.M900107-JLR200.
[30] K. Park, A.L. Scott, Cholesterol 25-hydroxylase production by dendritic cells
and macrophages is regulated by type I interferons, J. Leukoc. Biol. 88 (2010)
1081–1087, doi:http://dx.doi.org/10.1189/jlb.0610318.
[31] E.S. Gold, S.A. Ramsey, M.J. Sartain, J. Selinummi, I. Podolsky, D.J. Rodriguez,
et al., ATF3 protects against atherosclerosis by suppressing 25-
hydroxycholesterol-induced lipid body formation, J. Exp. Med. 209 (2012)
807–817. http://www.ncbi.nlm.nih.gov/pubmed/22473958.
[32] H. Lu, S. Talbot, K.A. Robertson, S. Watterson, T. Forster, D. Roy, et al., Rapid
proteasomal elimination of 3-hydroxy-3-methylglutaryl-CoA reductase by
interferon-gamma in primary macrophages requires endogenous 25-
hydroxycholesterol synthesis, Steroids (2015), doi:http://dx.doi.org/10.1016/j.
steroids.2015.02.022.
[33] E. Van Etten, C. Mathieu, Immunoregulation by 1,25-dihydroxyvitamin D3:
basic concepts, J. Steroid Biochem. Mol. Biol. (2005) 93–101.
[34] K. Stoffels, L. Overbergh, A. Giulietti, L. Verlinden, R. Bouillon, C. Mathieu,
Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human
monocytes, J. Bone Miner. Res. 21 (2006) 37–47.
[35] K. Edfeldt, P.T. Liu, R. Chun, M. Fabri, M. Schenk, M. Wheelwright, et al., T-cell
cytokines differentially control human monocyte antimicrobial responses by
regulating vitamin D metabolism, Proc. Natl. Acad. Sci. U. S. A. 107 (2010)
22593–22598.
[37] A.G. York, K.J. Williams, J.P. Argus, Q.D. Zhou, G. Brar, L. Vergnes, et al., Limiting
cholesterol biosynthetic flux spontaneously engages type i IFN signaling, Cell
163 (2015) 1716–1729.
[38] S. Hannedouche, J. Zhang, T. Yi, W. Shen, D. Nguyen, J.P. Pereira, et al.,
Oxysterols direct immune cell migration via EBI2, Nature 475 (2011) 524–527.
[39] L.M. Kelly, J.P. Pereira, T. Yi, Y. Xu, J.G. Cyster, EBI2 guides serial movements of
activated B cells and ligand activity is detectable in lymphoid and
nonlymphoid tissues, J. Immunol. 187 (2011) 3026–3032.
[40] F. Chalmin, V. Rochemont, C. Lippens, A. Clottu, A.W. Sailer, D. Merkler, et al.,
Oxysterols regulate encephalitogenic CD4+ T cell trafficking during central
nervous system autoimmunity, J. Autoimmun. 56 (2015) 45–55.
[41] B.A. Janowski, P.J. Willy, T.R. Devi, J.R. Falck, D.J. Mangelsdorf, An oxysterol
signalling pathway mediated by the nuclear receptor LXR alpha, Nature 383
(1996) 728–731, doi:http://dx.doi.org/10.1038/383728a0.
[42] A. Ito, C. Hong, X. Rong, X. Zhu, E.J. Tarling, P.N. Hedde, et al., LXRs link
metabolism to inflammation through Abca1-dependent regulation of
membrane composition and TLR signaling, Elife 4 (2015).
[43] H. Karlic, F. Varga, Impact of vitamin D metabolism on clinical epigenetics, Clin.
Epigenet. 2 (2011) 55–61.
[44] A. Takeuchi, G.S. Reddy, T. Kobayashi, T. Okano, J. Park, S. Sharma, Nuclear
factor of activated T cells (NFAT) as a molecular target for 1alpha,25-
dihydroxyvitamin D3-mediated effects, J. Immunol. 160 (1998) 209–218.
[45] Z. Bar-Shavit, S.L. Teitelbaum, P. Reitsma, A. Hall, L.E. Pegg, J. Trial, et al.,
Induction of monocytic differentiation and bone resorption by 1,25-
dihydroxyvitamin D3, Proc. Natl. Acad. Sci. U. S. A. 80 (1983) 5907–5911.Please cite this article in press as: S.Y. Bah, et al., Immune oxysterols: Role 
Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04.015[46] W.F. Rigby, L. Shen, E.D. Ball, P.M. Guyre, M.W. Fanger, Differentiation of a
human monocytic cell line by 1,25-dihydroxyvitamin D3 (calcitriol): a
morphologic, phenotypic, and functional analysis, Blood 64 (1984) 1110–1115.
[47] H. Xu, A. Soruri, R.K.H. Gieseler, J.H. Peters, 1,25-Dihydroxyvitamin D3 exerts
opposing effects to IL-4 on MHC class-II antigen expression, accessory activity,
and phagocytosis of human monocytes, Scand. J. Immunol. 38 (1993)
535–540.
[48] N.J. Kassebaum, A. Bertozzi-Villa, M.S. Coggeshall, K.A. Shackelford, C. Steiner,
K.R. Heuton, et al., Global, regional, and national levels and causes of maternal
mortality during 1990–2013: a systematic analysis for the Global Burden of
Disease Study 2013, Lancet 6736 (2014) 1–25, doi:http://dx.doi.org/10.1016/
S0140-6736(14)60696-6.
[49] F. Oberg, J. Botling, K. Nilsson, Functional antagonism between vitamin D3 and
retinoic acid in the regulation of CD14 and CD23 expression during monocytic
differentiation of U-937 cells, J. Immunol. 150 (1993) 3487–3495.
[50] T.-T. Wang, L.E. Tavera-Mendoza, D. Laperriere, E. Libby, N.B. MacLeod, Y. Nagai,
et al., Large-scale in silico and microarray-based identification of direct 1,25-
dihydroxyvitamin D3 target genes, Mol. Endocrinol. 19 (2005)
2685–2695.
[51] T.-T. Wang, F.P. Nestel, V. Bourdeau, Y. Nagai, Q. Wang, J. Liao, et al., Cutting
edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide
gene expression, J. Immunol. 173 (2004) 2909–2912.
[52] A.F. Gombart, N. Borregaard, H.P. Koeffler, Human cathelicidin antimicrobial
peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly
up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3, FASEB J. 19 (2005)
1067–1077.
[53] P.T. Liu, S. Stenger, H. Li, L. Wenzel, B.H. Tan, S.R. Krutzik, et al., Toll-like receptor
triggering of a vitamin D-mediated human antimicrobial response, Science 311
(2006) 1770–1773.
[54] M.B. Lowry, C. Guo, N. Borregaard, A.F. Gombart, Regulation of the human
cathelicidin antimicrobial peptide gene by 1a,25-dihydroxyvitamin D3 in
primary immune cells, J. Steroid Biochem. Mol. Biol. 143C (2014) 183–191.
http://www.ncbi.nlm.nih.gov/pubmed/24565560.
[55] F.B. Sow, W.C. Florence, A.R. Satoskar, L.S. Schlesinger, B.S. Zwilling, W.P. Lafuse,
Expression and localization of hepcidin in macrophages: a role in host defense
against tuberculosis, J. Leukoc. Biol. 82 (2007) 934–945.
[56] J. Bacchetta, J.J. Zaritsky, J.L. Sea, R.F. Chun, T.S. Lisse, K. Zavala, et al.,
Suppression of iron-regulatory hepcidin by vitamin D, J. Am. Soc. Nephrol.
(2013) 1–9. http://www.ncbi.nlm.nih.gov/pubmed/24204002.
[57] M. Cohen-Lahav, S. Shany, D. Tobvin, C. Chaimovitz, A. Douvdevani, Vitamin D
decreases NFkappaB activity by increasing IkappaBalpha levels, Nephrol.
Dial. Transplant. 21 (2006) 889–897, doi:http://dx.doi.org/10.1093/ndt/
gfi254.
[58] J.M. Matilainen, A. Räsänen, P. Gynther, S. Väisänen, The genes encoding
cytokines IL-2 IL-10 and IL-12B are primary 1a,25(OH)2D3 target genes, J.
Steroid Biochem. Mol. Biol. 121 (2010) 142–145.
[59] L. Adorini, G. Penna, Dendritic cell tolerogenicity in immunomodulation by
vitamin D receptor agonists, Hum. Immunol. (2009), doi:http://dx.doi.org/
10.1016/j.humimm.2009.01.016 S0198-8859(09)00021-4 [pii].
[60] M. Cippitelli, A. Santoni, Vitamin D3: a transcriptional modulator of the
interferon-gamma gene, Eur. J. Immunol. 28 (1998) 3017–3030, doi:http://dx.
doi.org/10.1002/(SICI)1521-4141(199810)28:10<3017:AID-IMMU3017>3.0.
CO;2-6.
[61] F. Baeke, H. Korf, L. Overbergh, E. van Etten, A. Verstuyf, C. Gysemans, et al.,
Human T lymphocytes are direct targets of 1,25-dihydroxyvitamin D3 in the
immune system, J. Steroid Biochem. Mol. Biol. 121 (2010)
221–227.
[62] A. Boonstra, F.J. Barrat, C. Crain, V.L. Heath, H.F. Savelkoul, A. O’Garra,
1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to
enhance the development of Th2 cells, J. Immunol. 167 (2001) 4974–4980.
http://www.ncbi.nlm.nih.gov/pubmed/11673504.
[63] D. D’Ambrosio, M. Cippitelli, M.G. Cocciolo, D. Mazzeo, P. Di Lucia, R. Lang, et al.,
Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of
NF-kB downregulation in transcriptional repression of the p40 gene, J. Clin.
Investig. 101 (1998) 252–262.
[64] G. Ferrara, B. Bleck, L. Richeldi, J. Reibman, L.M. Fabbri, W.N. Rom, et al.,
Mycobacterium tuberculosis induces CCL18 expression in human macrophages,
Scand. J. Immunol. 68 (2008) 668–674.
[65] L. Nguyen, J. Pieters, The Trojan horse: survival tactics of pathogenic
mycobacteria in macrophages, Trends Cell Biol. 15 (2005) 269–276.
[66] Z. Yang, Y. Kong, F. Wilson, B. Foxman, A.H. Fowler, C.F. Marrs, et al.,
Identification of risk factors for extrapulmonary tuberculosis, Clin. Infect. Dis.
38 (2004) 199–205, doi:http://dx.doi.org/10.1086/380644.
[67] S.K. Sharma, A. Mohan, A. Sharma, D.K. Mitra, Miliary tuberculosis: new
insights into an old disease, Lancet Infect. Dis. 5 (2005) 415–430, doi:http://dx.
doi.org/10.1016/S1473-3099(05)70163-8.
[68] C.V. Harding, W.H. Boom, Regulation of antigen presentation by
Mycobacterium tuberculosis: a role for Toll-like receptors, Nat. Rev. Microbiol. 8
(2010) 296–307.
[69] A.G. Bean, D.R. Roach, H. Briscoe, M.P. France, H. Korner, J.D. Sedgwick, et al.,
Structural deficiencies in granuloma formation in TNF gene-targeted mice
underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis
infection, which is not compensated for by lymphotoxin, J. Immunol. 162
(1999) 3504–3511, doi:http://dx.doi.org/10.4049/jimmunol.173.
6.4066.in mycobacterial infection and inflammation, J. Steroid Biochem. Mol.
12 S.Y. Bah et al. / Journal of Steroid Biochemistry & Molecular Biology xxx (2015) xxx–xxx
G Model
SBMB 4708 No. of Pages 12[70] M.G. Bonecini-Almeida, J.L. Ho, N. Boéchat, R.C. Huard, S. Chitale, H. Doo, et al.,
Down-modulation of lung immune responses by interleukin-10 and
transforming growth factor beta (TGF-beta) and analysis of TGF-beta receptors
I and II in active tuberculosis, Infect. Immun. 72 (2004) 2628–2634, doi:http://
dx.doi.org/10.1128/IAI.72.5.2628.
[71] P. Peyron, J. Vaubourgeix, Y. Poquet, F. Levillain, C. Botanch, F. Bardou, et al.,
Foamy macrophages from tuberculous patients’ granulomas constitute a
nutrient-rich reservoir for M. tuberculosis persistence, PLoS Pathog. 4 (2008).
[72] S.T. Cole, R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, et al.,
Deciphering the biology of Mycobacterium tuberculosis from the complete
genome sequence, Nature 393 (1998) 537–544.
[73] N.M. Nesbitt, X. Yang, P. Fontán, I. Kolesnikova, I. Smith, N.S. Sampson, et al., A
thiolase of Mycobacterium tuberculosis is required for virulence and production
of androstenedione and androstadienedione from cholesterol, Infect. Immun.
78 (2010) 275–282, doi:http://dx.doi.org/10.1128/IAI.00893-09.
[74] J.E. Griffin, J.D. Gawronski, M.A. DeJesus, T.R. Ioerger, B.J. Akerley, C.M. Sassetti,
High-resolution phenotypic profiling defines genes essential for mycobacterial
growth and cholesterol catabolism, PLoS Pathog. 7 (2011).
[75] A.K. Pandey, C.M. Sassetti, Mycobacterial persistence requires the utilization of
host cholesterol, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 4376–4380.
[76] S.M. Joshi, A.K. Pandey, N. Capite, S.M. Fortune, E.J. Rubin, C.M. Sassetti,
Characterization of mycobacterial virulence genes through genetic interaction
mapping, Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 11760–11765.
[77] X. Yang, E. Dubnau, I. Smith, N.S. Sampson, Rv1106c from Mycobacterium
tuberculosis is a 3beta-hydroxysteroid dehydrogenase, Biochemistry 46 (2007)
9058–9067.
[78] A. Brzostek, J. Pawelczyk, A. Rumijowska-Galewicz, B. Dziadek, J. Dziadek,
Mycobacterium tuberculosis is able to accumulate and utilize cholesterol, J.
Bacteriol. 191 (2009) 6584–6591, doi:http://dx.doi.org/10.1128/JB.00488-09.
[79] J.K. Capyk, I. D’Angelo, N.C. Strynadka, L.D. Eltis, Characterization of 3-
ketosteroid 9beta-hydroxylase, a Rieske oxygenase in the cholesterol
degradation pathway of Mycobacterium tuberculosis, J. Biol. Chem. 284 (2009)
9937–9946.
[80] C. Astarie-Dequeker, L. Le Guyader, W. Malaga, F.K. Seaphanh, C. Chalut, A.
Lopez, et al., Phthiocerol dimycocerosates of M. tuberculosis participate in
macrophage invasion by inducing changes in the organization of plasma
membrane lipids, PLoS Pathog. 5 (2009).Please cite this article in press as: S.Y. Bah, et al., Immune oxysterols: Role 
Biol. (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.04.015[81] J.K. Capyk, R. Kalscheuer, G.R. Stewart, J. Liu, H. Kwon, R. Zhao, et al.,
Mycobacterial cytochrome P450 125 (Cyp125) catalyzes the terminal
hydroxylation of C27 steroids, J. Biol. Chem. 284 (2009) 35534–35542.
[82] J.C. Chang, N.S. Harik, R.P. Liao, D.R. Sherman, Identification of Mycobacterial
genes that alter growth and pathology in macrophages and in mice, J. Infect.
Dis. 196 (2007) 788–795.
[83] R.A. Slayden, R.E. Lee, C.E. Barry, Isoniazid affects multiple components of the
type II fatty acid synthase system of Mycobacterium tuberculosis, Mol.
Microbiol. 38 (2000) 514–525.
[84] R. Rawat, A. Whitty, P.J. Tonge, The isoniazid-NAD adduct is a slow, tight-
binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase:
adduct affinity and drug resistance, Proc. Natl. Acad. Sci. U. S. A. 100 (2003)
13881–13886.
[85] R. Gande, K.J.C. Gibson, A.K. Brown, K. Krumbach, L.G. Dover, H. Sahm, et al.,
Acyl-CoA carboxylases (accD2 and accD3), together with a unique polyketide
synthase (Cg-pks), are key to mycolic acid biosynthesis in Corynebacterianeae
such as Corynebacterium glutamicum and Mycobacterium tuberculosis, J. Biol.
Chem. 279 (2004) 44847–44857, doi:http://dx.doi.org/10.1074/jbc.
M408648200.
[86] S.P. Parihar, R. Guler, R. Khutlang, D.M. Lang, R. Hurdayal, M.M. Mhlanga, et al.,
Statin therapy reduces the Mycobacterium tuberculosis burden in human
macrophages and in mice by enhancing autophagy and phagosome
maturation, J. Infect. Dis. 209 (2014) 754–763.
[87] L.S. Lobato, P.S. Rosa, J.D.S. Ferreira, A.D.S. Neumann, M.G. Da Silva, D.C. Do
Nascimento, et al., Statins increase rifampin mycobactericidal effect,
Antimicrob. Agents Chemother. 58 (2014) 5766–5774, doi:http://dx.doi.org/
10.1128/AAC.01826-13.
[88] H. Salamon, N. Bruiners, K. Lakehal, L. Shi, J. Ravi, K.D. Yamaguchi, et al., Cutting
edge: vitamin D regulates lipid metabolism in Mycobacterium tuberculosis
infection, J. Immunol. 193 (2014) 30–34. http://www.ncbi.nlm.nih.gov/
pubmed/24899504.
[89] G. Ferrari, H. Langen, M. Naito, J. Pieters, A coat protein on phagosomes
involved in the intracellular survival of mycobacteria, Cell 97 (1999) 435–447.
[90] P.K. Anand, D. Kaul, M. Sharma, Synergistic action of vitamin D and retinoic
acid restricts invasion of macrophages by pathogenic mycobacteria, J.
Microbiol. Immunol. Infect. 41 (2008) 17–25.in mycobacterial infection and inflammation, J. Steroid Biochem. Mol.
